ArticleHIV medicine2025
Long-term risk and predictors of high-risk human papillomavirus persistence after thermal ablation amongst women living with HIV in West Africa.
Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionMounting evidence supports the use of thermal ablation in women positively screened with high-risk Human Papillomaviruses (hrHPV) but limited data are available on the long-term post-treatment outcomes in women living with HIV (WLHIV). We aimed to estimate the persistence of hrHPV infection amongst WLHIV ≥24 months post treatment in West Africa.
methodsFrom October 2019 to October 2024, a cohort study was conducted amongst WLHIV in two HIV clinics in Burkina Faso and Cote d'Ivoire. All WLHIV with a positive hrHPV test who received thermal ablation were followed up ≥24 months. During follow-up visits, DNA HPV testing, visual inspection and biopsy were systematically performed. Factors associated with ≥24 months hrHPV positivity were assessed through a logistic regression model.
resultsA total of 200 WLHIV, aged 42 years [Interquartile range (IQR): 38-45], with a nadir CD4 of 365 [IQR: 168-616] cell/mm
conclusionPost-therapeutic hrHPV infection remains high beyond 2 years in WLHIV stressing the need for long-term follow-up, especially when diagnosed with advanced HIV disease. Future implementation research should focus on the contribution of additional tools to better track those in need of additional treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.